Casgevy Gene Therapy Brings Relief to Sickle Cell Disease Patient

Published on Mass General Brigham

After years of debilitating pain from sickle cell disease, Allan Byamukama became one of the first patients to receive Casgevy, an FDA-approved gene therapy that reactivates fetal hemoglobin to counteract sickled red blood cells. The treatment, which includes stem cell collection, genetic editing, and intensive chemotherapy, has greatly reduced Allan’s pain crises. Blood tests show improved hemoglobin levels and red cell lifespan. Though not a cure, Casgevy offers a meaningful improvement in quality of life. Allan now looks forward to completing his graduate studies and living without constant hospital visits.

👉 Finding Relief After Years of Unbearable Pain from Sickle Cell Disease: Allan's Story

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.